Vanguard Asset Management
KALV

Vanguard Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Vanguard Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,324
Closed -$349K – 2469
2026
Q1 		$349K Buy
+17,324
New +$279K ﹤0.01% 2247

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Asset Management's KALV Position: Q2 2026 in Review

Vanguard Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 17,324 shares — an estimated $349K sold.

Vanguard Asset Management first reported a position in KALV in Q1 2026 and held it in 1 quarter. The position peaked at $349K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Vanguard Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Asset Management sold 17,324 KalVista Pharmaceuticals shares in Q2 2026, an estimated $349K.
  • Vanguard Asset Management first reported a position in KalVista Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Asset Management's KalVista Pharmaceuticals position peaked at $349K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.